Venous thromboembolism: A Call for risk assessment in all hospitalised patients

Thrombosis is a major contributor to the global burden of disease because it is the pathology underlying venous thromboembolism (VTE), ischaemic heart disease, and ischaemic stroke ([1]). Collectively, these disorders account for about 1 in 4 deaths worldwide ([1]). Prevention and treatment of thrombosis are critical for reducing global death and disability.

In 2014, the International Society on Thrombosis and Haemostasis (ISTH) declared October 13 as World Thrombosis Day to increase global awareness about thrombosis, including its risk factors and strategies for prevention, diagnosis, and treatment. VTE was selected as the initial focus of World Thrombosis Day because well-established public awareness campaigns were already focusing on heart disease and stroke through World Heart and World Stroke Days. More specifically, hospital-associated VTE was chosen as the focus for increased awareness and action.

This decision was supported by several pieces of evidence. First, there are compelling data from Europe and the United States documenting the burden of VTE, which includes deep-vein thrombosis (DVT) and pulmonary embolism (PE). Cohen et al. estimated that in 2004 there were more than 600,000 DVT events, 400,000 PE events, and 500,000 VTE-related deaths, across the European Union ([2]). In the United States, investigators from the Centers for Disease Control and Prevention estimated that there were more than 500,000 adult hospitalisations with a diagnosis of VTE each year from 2007 to 2009 ([3]). VTE is responsible for more deaths each year than breast cancer, HIV disease, and motor vehicle crashes combined ([2]).

Second, the available epidemiologic data indicate that approximately 60 % of cases of VTE are associated with a recent hospital stay ([4]). The World Health Organisation (WHO) patient safety program found that hospital-associated VTE was a leading cause of death and disability associated with hospitalisation in low, middle, and high income countries and accounted for more deaths and greater disability than nosocomial pneumonia, catheter-related bloodstream infections, and adverse drug events ([5]).

Public awareness about VTE is low, and lags behind that of other common disorders ([6]). In a global survey, only 44 % and 54 % of respondents were aware of DVT and PE, respectively, and only 45 % of respondents were aware that most cases of VTE were preventable ([6]). Even fewer identified hospitalisation as a risk factor ([6]). An important educational goal of World Thrombosis Day is to arm patients and their families with information to be their own advocates for VTE prevention in high risk settings, such as hospitalisation.

^* See Appendix for Steering Committee members.

• References

• 1 ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. Thromb Haemost 2014; 112: 843-852.
• 2 Cohen AT, Agnelli G, Anderson FA. et al. VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007; 98: 756-764.
• 3 Yusuf HR, Tsai J, Atrash HK. et al. Venous throm-boembolism in adult hospitalisations - United States, 2007-2009. MMWR Morb Mortal Wkly Rep 2012; 61: 401-404.
• 4 Heit JA. The epidemiology of venous thromboem-bolism in the community. Arterioscler Thromb Vasc Biol 2008; 28: 370-372.
• 5 Jha AK, Larizgoitia I, Audera-Lopez C. et al. The global burden of unsafe medical care: analytic modelling of observational studies. BMJ Qual Saf 2013; 22: 809-815.
• 6 Wendelboe AM, McCumber M, Hylek EM. et al. for the ISTH Steering Committee for World Thrombosis Day. Global public awareness of venous thromboembolism. J Thromb Haemost 2015; 13: 1365-1371.
• 7 Qasseem A, Chou R, Humphrey LL. et al. for the Clinical Guidelines Committee of the American College of Physicians. Venous thromboembolism prophylaxis in hospitalised patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011; 155: 625-632.
• 8 Kahn S, Lim W, Dunn AS. et al. American College of Chest Physicians. Prevention of VTE in nonsur-gical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141 (02) Suppl e195S-226S.
• 9 Gould MK, Garcia DA, Wren SM. et al. American College of Chest Physicians. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141 (02) Suppl e227S-277S.
• 10 Falck-Yitter Y, Francis CW, Johanson NA. et al. American College of Chest Physicians. Prevention of VTE in orthopedic surgery patients: Anti-thrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-based Clinical Practice Guidelines. Chest 2012; 141 (02) Suppl e278S-325S.
• 11 Nicolaides AN, Fareed J, Kakkar AK. et al. Prevention and treatment of venous thromboembolism - international consensus statement. Int Angiol 2013; 32: 111-260.
• 12 Cohen AT, Tapson VF, Bergmann JF. et al. ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet 2008; 371: 387-94. Erratum in: Lancet 2008; 371: 1914.
• 13 Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon 2005; 51: 70-78.
• 14 Bahl V, Hu HM, Henke PK. et al. A validation study of a retrospective venous thromboembolism risk scoring method. Ann Surg 2010; 251: 344-350.
• 15 Spyropoulos AC, Anderson FA, Fitzgerald G. et al. Predictive and associative models to identify hospitalised medical patients at risk for VTE. Chest 2011; 140: 706-714.
• 16 Spyropoulos AC, McGinn T, Khorana A. The use of weighted and scored risk assessment models for venous thromboembolism. Thromb Hamost 2012; 108: 1072-1076.
• 17 Huang W, Anderson FA, Spencer FA. et al. Risk-assessment models for predicting venous throm-boembolism among hospitalised non-surgical patients: a systematic review. J Thromb Thrrombolysis 2013; 35: 67-80.
• 18 Mahan CE, Liu Y, Turpie AG. et al. External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR). Thromb Ha-most 2014; 112: 692-699.
• 19 Rosenberg D, Eichorn A, Alarcon M. et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc 2014; 03: e001152. doi:10.1161/JAHA 114.001152
• 20 Obi AT, Pannucci C, Nackashi A. et al. Validation of the Caprini Venous Thromboembolism Risk Assessment Model in Critically Ill Surgical Patients. JAMA Surgery 2015; 150: 941-948.
• 21 Green MT, Spyropoulos AC, Chopra V. et al. Validation of risk assessment models of venous throm-boembolism in hospitalised medical patients. Am J Med 2016; 129
• 22 Cohen AT, Spiro TE, Spyropoulos AC. et al. D-dimer as a predictor of venous thromboembol-ism in acutely ill hospitalised patients: a subanaly-sis of the randomised controlled MAGELLAN trial. J Thromb Haemost 2014; 12: 479-487.
• 23 Department of Health (2010) Venous Throm-boembolism (VTE) Risk Assessment. Available at: https://dh.gov.uk/en/Publicationsandstatistics/PublicationsPolicyAndGuidance/DH_088215
• 24 Lester W, Freemantle N, Begaj I. et al. Fatal venous thromboembolism associated with hospital admission: a cohort study to assess the impact of a national risk assessment target. Heart 2013; 99: 1734-1739.
• 25 Catterick D, Hunt BJ. Impact of the national venous thromboembolism risk assessment tool in secondary care in England: retrospective population-based database study. Blood Coagul Fibrinolysis 2014; 25: 571-576.
• 26 Cassidy MR, Rosenkranz P, McAneny D. Reducing postoperative venous thromboembolism complications with a standardised risk-stratified prophylaxis protocol and mobilisation program. J Am Coll Surg 2014; 218: 1095-1104.
• 27 Cohen AT, Harrington RA, Goldhaber SZ. et al. for the APEX Investigators. Extended thrombo-prophylaxis with betrixaban in acutely ill medical patients. N Engl J Med 2016; 375: 534-544.
• 28 Raskob G, Spyropoulos AC, Zrubeck J. et al. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thromb Haemost 2016; 115: 1240-1248.
• 29 Grosse SD, Nelson RE, Nyarko KA. et al. The economic burden of incident venous thromboem-bolism in the United States: a review of estimated attributable healthcare costs. Thrombosis Res 2016; 137: 3-10.